Edition:
United Kingdom

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

4.81USD
8:00pm GMT
Change (% chg)

$0.08 (+1.69%)
Prev Close
$4.73
Open
$4.75
Day's High
$4.89
Day's Low
$4.61
Volume
121,604
Avg. Vol
194,251
52-wk High
$11.64
52-wk Low
$3.35

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

  INSY.OQ Industry Sector
P/E (TTM): -- 69.32 32.54
EPS (TTM): -0.21 -- --
ROI: -5.71 8.89 13.82
ROE: -5.88 10.00 15.25

Insys Therapeutics' auditor raises going concern doubts, shares drop

Insys Therapeutics Inc said on Wednesday its auditor raised doubts on the drugmaker's ability to continue as a going concern, sending its shares down 13 percent.

13 Mar 2019

UPDATE 1-Insys Therapeutics' auditor raises going concern doubts, shares drop

March 13 Insys Therapeutics Inc said on Wednesday its auditor raised doubts on the drugmaker's ability to continue as a going concern, sending its shares down 13 percent.

13 Mar 2019

Insys Therapeutics' auditor raises going concern doubts, shares drop

March 13 Insys Therapeutics Inc said on Wednesday its auditor raised doubts on the drugmaker's ability to continue as a going concern, sending its shares down as much as 10 percent.

13 Mar 2019

Insys says Lazard hired to advise on options, in talks to divest Subsys

Insys Therapeutics Inc said it tapped Lazard to advise the drugmaker on its plans to explore strategic options and is in talks to divest its fentanyl sublingual spray Subsys, sending the company's shares down 15 percent in after-hours trading.

08 Mar 2019

Insys says Lazard hired to advise on options, in talks to divest Subsys

March 7 Insys Therapeutics Inc said it tapped Lazard to advise the drugmaker on its plans to explore strategic options and is in talks to divest its fentanyl sublingual spray Subsys, sending the company's shares down 15 percent in after-hours trading.

07 Mar 2019

Insys executive gave doctor lap dance while promoting drug, witness says

BOSTON An ex-stripper who became a regional sales director at Insys Therapeutics Inc gave a doctor a lap dance at a Chicago club as the drugmaker pushed the doctor to prescribe its addictive fentanyl spray, a former Insys employee testified on Tuesday.

30 Jan 2019

Insys exec gave doctor lap dance while promoting drug, witness says

BOSTON, Jan 29 An ex-stripper who became a regional sales director at Insys Therapeutics Inc gave a doctor a lap dance at a Chicago club as the drugmaker pushed the doctor to prescribe its addictive fentanyl spray, a former Insys employee testified on Tuesday.

29 Jan 2019

'Greed' fueled Insys founder's opioid bribe scheme: prosecutor

BOSTON A lawyer for Insys Therapeutics Inc's one-time billionaire founder on Monday denied that he had any role in the U.S. opioid crisis as a federal prosecutor told jurors he ran a scheme to bribe doctors to prescribe an addictive fentanyl spray.

28 Jan 2019

UPDATE 3-'Greed' fueled Insys founder's opioid bribe scheme -prosecutor

BOSTON, Jan 28 A lawyer for Insys Therapeutics Inc's one-time billionaire founder on Monday denied that he had any role in the U.S. opioid crisis as a federal prosecutor told jurors he ran a scheme to bribe doctors to prescribe an addictive fentanyl spray.

28 Jan 2019

Insys founder, former execs face opioid kickback scheme trial

BOSTON, Jan 28 The one-time billionaire founder of Insys Therapeutics Inc and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales.

28 Jan 2019

Earnings vs. Estimates